奥氮平联合三联止吐方案治疗顺铂化疗多日患者的疗效观察  

作　　者：张艳 丁玲玉 钱新宇[1] 

机构地区：[1]杭州市肿瘤医院,310000

出　　处：《浙江临床医学》2024年第8期1172-1174,共3页Zhejiang Clinical Medical Journal

摘　　要：目的探讨奥氮平联合三联止吐方案预防顺铂多日化疗患者发生CINV的疗效与安全性。方法选取2018年9月至2023年4月接受顺铂化疗三日患者46例,分为观察组和对照组,每组各23例,对照组予常规三联止吐方案,观察组在对照组基础上加用口服奥氮平5 mg D1~5,比较两组化疗后D1~7恶心呕吐的发生情况及不良反应。结果两组急性CINV发生率及完全缓解率、延迟性CINV发生率及完全缓解率和全期发生率及完全缓解率比较,差异有统计学意义(P<0.05)。观察组使用奥氮平期间头晕发生率为4.3%,嗜睡发生率为4.3%,观察组中有5例患者在应用奥氮平后睡眠较前有所改善。结论奥氮平联合三联止吐方案减少顺铂多日化疗方案引起的急性期与延迟期CINV,且不良反应可耐受。Objective To research the efficacy and safety of olanzapine combined with a triple antiemetic regimen for the prevention of CINV in patients undergoing multiple days of cisplatin chemotherapy.Methods Forty-six patients receiving three days of cisplatin chemotherapy from September 2018 to April 2023 were divided into an observation group and a control group,with 23 patients in each group.The control group was given the conventional triple antiemetic regimen,and the observation group additionally added olanzapine 5 mg D1~5 orally each night.To observe the occurrence of D1~7 nausea and vomiting in both groups after chemotherapy and the adverse effects after using olanzapine.Results Comparison of acute CINV incidence and complete remission rate,delayed CINV incidence and complete remission rate,and full-stage incidence and complete remission rate between the two groups was statistically significant(P<0.05).The incidence of dizziness was 4.3%(1/23)and drowsiness was 4.3%(1/23)during the use of olanzapine in the observation group,and five patients in the observation group had improved sleep after the application of olanzapine.Conclusion Olanzapine combined with a triple antiemetic regimen reduces acute and delayed CINV induced by a three-day cisplatin-containing chemotherapy regimen and the adverse effects were tolerable.

关 键 词：奥氮平 顺铂 多日化疗 CINV 

分 类 号：R730.5[医药卫生—肿瘤]